clone 1g9 cat Search Results


dshb gfp 12a6 rrid ab 2617417  (Developmental Studies Hybridoma Bank)
95
Developmental Studies Hybridoma Bank dshb gfp 12a6 rrid ab 2617417

Dshb Gfp 12a6 Rrid Ab 2617417, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dshb gfp 12a6 rrid ab 2617417/product/Developmental Studies Hybridoma Bank
Average 95 stars, based on 1 article reviews
dshb gfp 12a6 rrid ab 2617417 - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
anti tigit antibodies  (Bio X Cell)
95
Bio X Cell anti tigit antibodies
a Treatment schedule for female C57BL/6 mice injected with Vk12598 MM cells (t-VkMYC) conditioned with P.m . or vehicle (PBS) and receiving αTIGIT or IgG. b Body weight variation since tumor cell injection. Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data are presented as mean ± SD. Statistical analysis by One-way Anova. c , d M-spike appearance since tumor injection ( c ) and overall survival (OS; d ). Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data pooled from two independent experiments. Statistical analysis by Log-rank (Mantel–Cox) test. ns: not significant. Source data are provided as a Source Data file.
Anti Tigit Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti tigit antibodies/product/Bio X Cell
Average 95 stars, based on 1 article reviews
anti tigit antibodies - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
tigit 1g9; bv650  (Becton Dickinson)
90
Becton Dickinson tigit 1g9; bv650
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Tigit 1g9; Bv650, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tigit 1g9; bv650/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
tigit 1g9; bv650 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
icos bv421  (Becton Dickinson)
90
Becton Dickinson icos bv421
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Icos Bv421, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/icos bv421/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
icos bv421 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
capture antibody (clone 1g9)  (Abnova)
90
Abnova capture antibody (clone 1g9)
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Capture Antibody (Clone 1g9), supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/capture antibody (clone 1g9)/product/Abnova
Average 90 stars, based on 1 article reviews
capture antibody (clone 1g9) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cd62l fitc  (Becton Dickinson)
90
Becton Dickinson cd62l fitc
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd62l Fitc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd62l fitc/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd62l fitc - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cd44 bv786  (Becton Dickinson)
90
Becton Dickinson cd44 bv786
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd44 Bv786, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd44 bv786/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd44 bv786 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cd62l bv510 1/100  (Becton Dickinson)
90
Becton Dickinson cd62l bv510 1/100
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd62l Bv510 1/100, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd62l bv510 1/100/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd62l bv510 1/100 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
icos pe 1/100  (Becton Dickinson)
90
Becton Dickinson icos pe 1/100
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Icos Pe 1/100, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/icos pe 1/100/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
icos pe 1/100 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
tim3 bv650 1/50 5d12  (Becton Dickinson)
90
Becton Dickinson tim3 bv650 1/50 5d12
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Tim3 Bv650 1/50 5d12, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tim3 bv650 1/50 5d12/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
tim3 bv650 1/50 5d12 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cd25 bv605 1/50  (Becton Dickinson)
90
Becton Dickinson cd25 bv605 1/50
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Cd25 Bv605 1/50, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd25 bv605 1/50/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd25 bv605 1/50 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
icos pe 1/100 7e.17g9  (Becton Dickinson)
90
Becton Dickinson icos pe 1/100 7e.17g9
a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 <t>(TIGIT,</t> Ly6C, GzmB, FR4, IL-10Rα, CD160), <t>6</t> <t>(Ly6A),</t> and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.
Icos Pe 1/100 7e.17g9, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/icos pe 1/100 7e.17g9/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
icos pe 1/100 7e.17g9 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Journal: eLife

Article Title: A Drosophila model of neuronal ceroid lipofuscinosis CLN4 reveals a hypermorphic gain of function mechanism

doi: 10.7554/eLife.46607

Figure Lengend Snippet:

Article Snippet: The following antibodies and dilutions were used: rabbit anti-CSPα, 1:2000 (Enzo Life Sciences Cat# VAP-SV003E, RRID: AB_2095057 ); mouse anti-dCSP, 1:250 (DSHB Cat# DCSP-1 (ab49), RRID: AB_2307345; ); mouse anti-GFP, 1:1000 (DSHB Cat# DSHB-GFP-12A6, RRID: AB_2617417 ); guinea pig anti-HRS, 1:2000; , H. Bellen, Baylor College of Medicine, Houston, TX); rat anti-HA, 1:200 (Roche Cat# 3F10, RRID: AB_2314622 ); rabbit anti-GM130, 1:200 (Abcam Cat# ab31561, RRID: AB_2115328 ); goat anti-Golgin245, 1:2000 (DSHB Cat# Golgin245, RRID: AB_2618260 ), goat anti-GMAP, 1:2000 (DSHB Cat# GMAP, RRID: AB_2618259 ); mouse anti Rab7, 1:100 (DSHB Cat# Rab7, RRID: AB_2722471; ); mouse anti-Syx1A, 1:200 (DSHB Cat# 8c3, RRID: AB_528484 ); mouse anti-ubiquitin-conjugated protein, 1:2000 (Enzo Life Sciences Cat# BML-PW8810, RRID: AB_10541840 ); goat anti-HRP Alexa Fluor 647-conjugated, 1:500 (Jackson ImmunoResearch Labs Cat# 123-605-021, RRID: AB_2338967 ); goat anti-mouse IgG1 Alexa Fluor 488-conjugated, 1:500 (Thermo Fisher Scientific Cat# A-21121, RRID: AB_2535764 ); donkey anti-rabbit IgG (H+L) Cy3-conjugated, 1:500 (Jackson ImmunoResearch Labs Cat# 711-165-152, RRID: AB_2307443 ); goat anti-guinea pig IgG (H+L) Alexa Fluor 488-conjugated, 1:1000 (Thermo Fisher Scientific Cat# A-11073, RRID: AB_2534117 ); goat anti-rat IgG (H+L) Alexa Fluor 488-conjugated, 1:500 (Jackson ImmunoResearch Labs Cat# 112-545-167, RRID: AB_2338362 ).

Techniques: Sequencing, Construct, Recombinant, Plasmid Preparation, Clone Assay, Mutagenesis, Transformation Assay, Generated, Immunostaining, Western Blot, Software

a Treatment schedule for female C57BL/6 mice injected with Vk12598 MM cells (t-VkMYC) conditioned with P.m . or vehicle (PBS) and receiving αTIGIT or IgG. b Body weight variation since tumor cell injection. Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data are presented as mean ± SD. Statistical analysis by One-way Anova. c , d M-spike appearance since tumor injection ( c ) and overall survival (OS; d ). Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data pooled from two independent experiments. Statistical analysis by Log-rank (Mantel–Cox) test. ns: not significant. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma

doi: 10.1038/s41467-025-65312-y

Figure Lengend Snippet: a Treatment schedule for female C57BL/6 mice injected with Vk12598 MM cells (t-VkMYC) conditioned with P.m . or vehicle (PBS) and receiving αTIGIT or IgG. b Body weight variation since tumor cell injection. Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data are presented as mean ± SD. Statistical analysis by One-way Anova. c , d M-spike appearance since tumor injection ( c ) and overall survival (OS; d ). Vehicle + IgG: n = 10; Veh + αTIGIT: n = 11; P.m .+ αTIGIT: n = 14. Data pooled from two independent experiments. Statistical analysis by Log-rank (Mantel–Cox) test. ns: not significant. Source data are provided as a Source Data file.

Article Snippet: Anti-TIGIT antibodies (Clone 1G9, Cat. BE0274, BioxCell) or isotype control antibodies (mouse IgG1 isotype; Cat. BE0083, BioxCell; 200 μg/dose) were administered twice per week to t-VkMYC mice pretreated as described above. t-VkMYC mice were weekly bled for M-spike quantification.

Techniques: Injection

a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Nature Communications

Article Title: Antigen-driven EGR2 expression is required for exhausted CD8 + T cell stability and maintenance

doi: 10.1038/s41467-021-23044-9

Figure Lengend Snippet: a – e H2-D b GP 33-41 tetramer-stained CD8 + T cells were sorted from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i., and subjected to multiplexed scRNAseq. a tSNE plot showing clusters identified within the pooled WT and cKO cells using published signatures. b Proportional distribution of the clusters identified in a within WT and cKO cells. c tSNE plot from a showing the location of WT (aqua) and cKO (orange) cells. d Volcano plots generated by comparing gene expression within cKO vs WT cells in each cluster from a . Dotted lines indicate p -value (0.05) and log 2 fold change (>0.8 or <−0.8) cut-off values. Red dots indicate genes that satisfy both p -value and fold change cut-offs, while blue dots indicate genes that satisfy the p -value but not the fold change cut-off. Genes up in cKO are on the right, while genes up in WT are on the left. e GSEA analysis of the comparisons from d looking at enrichment of genes selectively upregulated in exhaustion (“Exhaustion signature”; upper plots in red), or genes selectively up in effector cells at day 8 of acute vs chronic LCMV (“Effector signature”; lower plots in blue). f , g Differentially expressed markers identified by the scRNAseq analysis in d were confirmed in H2-D b GP 33–41 tetramer-stained CD8 + T cells from CD4-depleted, chronic LCMV infected WT or cKO mice at day 20 p.i. Representative plots ( f ) and pooled data ( g ) are shown. For the markers in g , WT n = 20 (PD-1, EOMES), 10 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), and KO n = 22 (PD-1, EOMES), 12 (TIGIT, Ly6C, GzmB, FR4, IL-10Rα, CD160), 6 (Ly6A), mice per group from 2–5 independent experiments. p -values were calculated using a two-tailed Mann–Whitney test (TCF1 - Ly6C, TCF1 - Ly6A, TCF1 + GzmB, TCF1 - GzmB, TCF1 + CD160) or a two-tailed unpaired T test (all others). For indicated significant differences, exact p values (left to right graphs) for TCF1 + = <0.0001, 0.0466, 0 . 0014, 0.0015, 0.0056, 0.0070, <0.0001, <0.0001, for TCF1 − = <0.0001, <0.0001, 0.0059, 0.0090, 0.0411, <0.0001, 0.0084. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The following antibodies were used for staining (purchased from Biolegend unless otherwise stated): CD8α (clone 53-6.7; PerCP (1/100, Cat. no. 100732), BV421 (1/200, Cat. no. 100738), BUV395 (1/200, BD Biosciences Cat. no. 563786) and BUV805 (1/200, BD Biosciences Cat. no. 563786)), CD44 (clone IM7; Pacific Blue (1/400, Cat. no. 103020), BUV737 (1/1000, BD Biosciences Cat. no. 612799)), CD107a (clone 1D4B; FITC (1/400, Cat. no. 121606)), IFNγ (clone XMG1.2; PE-Cy7 (1/2000, eBioscience Cat. no. 25-7311-41), TNFα (clone MP6-XT22; PE (1/2000, Cat. no. 506306)), IL-2 (clone JES6-5H4; APC (1/100, eBioscience Cat. no. 17-7021-82)), CD45.1 (clone A20; FITC (1/200, BD Biosciences Cat. no. 553775)), CD45.2 (clone 104; BUV395 (1/200, BD Biosciences Cat. no. 564616)), Ly6C (clone AL21; FITC (1/200, BD Biosciences Cat. no. 553104)), PD-1 (clone 29F.1A12; BV785 (1/100, Cat. no. 135225)), Tim3 (clone RMT3-23; BV605 (1/100, Cat. no. 119721)), 2B4 (clone 2B4; FITC (1/50, BD Biosciences Cat. no. 553305)), Lag3 (clone C9B7W; PE (1/100, Cat. no. 125208)), CD160 (clone 7H1; PE-Cy7 (1/100, Cat. no. 143010)), Egr2 (clone erongr2; PE (1/50, eBioscience Cat. no. 143010)), TCF1 (clone C63D9; unconjugated (1/100, Cell Signaling Technologies Cat. no. 2203S) followed by a secondary antibody (Goat anti-Rabbit Alexa594 (1/1000, Invitrogen Cat. no. A11012))), CXCR5 (clone 2G8; BV421 (1/25, BD Biosciences Cat. no. 562856)), Slamf6 (clone 13G3; PE (1/200, BD Biosciences Cat. no. 561540), BV421 (1/200, BD Biosciences Cat. no. 740090)), CD101 (clone Moushi101; PE-Cy7 (1/200, eBioscience Cat. no. 25-1011-82)), CD127 (clone A7R34; PE-Cy7 (1/100, Cat. no. 135014)), TIGIT (clone 1G9; BV650 (1/100, BD Biosciences Cat. no. 744213)), Ly6A/E (clone E13-161.7; PE (1/200, BD Biosciences Cat. no. 553336)), GzmB (clone GB11; PE (1/200, eBioscience Cat. no. GRB04)), FR4 (clone eBio12A5; PE-Cy7 (1/100, eBioscience Cat. no. 25-5445-82)), IL-10Rα (clone 1B1.3a; PE (1/100, Cat. no. 112706)), KLRG1 (clone 2F1; FITC (1/200, eBioscience Cat. no. 11-5893-82)), CD62L (clone MEL-14; APC-Cy7 (1/200, Cat. no. 104428)), Eomes (clone Dan11mag; Alexa488 (1/50, eBioscience Cat. no. 53-4875-82)), ppErk1/2 (clone 197G2; Alexa647 (1/100, Cell Signaling Technologies Cat. no. 13148S)), and pS6 (clone D57.2.2E; Alexa488 (1/100, Cell Signaling Technologies Cat. no. 4803S)).

Techniques: Staining, Infection, Generated, Expressing, Two Tailed Test, MANN-WHITNEY